EMA-Gate: PharmaMar wins suit against EMA
The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
/in News/by Thomas GabrielczykDanish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx […]
Anacura aquires Ohmx.bio
/in News/by Thomas GabrielczykMerger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
Ten drug recommendations by EMA
/in News/by Thomas GabrielczykEMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.
Semarion Ltd. wins Ignite SME award at SLAS Europe
/in News/by Thomas GabrielczykUK-based Semarion Ltd. was honoured as the most innovative company in the field of laboratory automation at SLAS Europe 2024 in Barcelona. <br /><br /><br />
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
/in News/by Thomas GabrielczykUS pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones. <div></div>
SLAS Europe 2024 honours products with most impact
/in News/by Thomas GabrielczykSwiss Seed Biosciences SA and UK-based Cryologyx Ltd have won the SLAS Europe Product Award 2024 for product developments with transformational potential for the sector.
Hornet Therapeutics reports first data of EBV-triggered disease blocker
/in News/by Thomas GabrielczykHornet Therapeutics Ltd will use a US$5m seed financing to launch clinical tests of its IDO1 blocker HTX-201within the next 12 to 18 months to target post-transplant lymphoproliferative disease.
AstraZeneca puts step into obesity market
/in News/by Thomas GabrielczykSwiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.
LabGenius raises £35m to expand its antibody discovery platform
/in News/by Thomas GabrielczykLondon-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.